{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:03:08Z","timestamp":1792508588332,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["FARM9RCP52"],"award-info":[{"award-number":["FARM9RCP52"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.annonc.2023.10.095","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T15:33:08Z","timestamp":1699025588000},"page":"118-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed\/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial"],"prefix":"10.1016","volume":"35","author":[{"given":"M.","family":"Ladetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-7806","authenticated-orcid":false,"given":"R.","family":"Tavarozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Botto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Volpetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.R.","family":"Zilioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"G.","family":"Gaidano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ghiggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1558-371X","authenticated-orcid":false,"given":"D.","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-6124","authenticated-orcid":false,"given":"A.J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Latte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pennese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-9580","authenticated-orcid":false,"given":"E.","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Boccomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Anastasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bottelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2023.10.095_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.annonc.2023.10.095_bib2","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1182\/blood-2013-12-545954","article-title":"Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?","volume":"123","author":"Tellier","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.10.095_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annonc.2023.10.095_bib4","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.10.095_bib5","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.10.095_bib6","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.095_bib7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2023.10.095_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2023.10.095_bib9","first-page":"486","article-title":"Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.10.095_bib10","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.095_bib11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.095_bib12","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.10.095_bib13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2023.10.095_bib14","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2006-10-041863","article-title":"How I treat indolent lymphoma","volume":"109","author":"Gribben","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.10.095_bib15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.10.095_bib16","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2023.10.095_bib17","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.annonc.2023.10.095_bib18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annonc.2023.10.095_bib19","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.095_bib20","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.095_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clml.2011.04.009","article-title":"Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma","volume":"11","author":"Karmali","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.annonc.2023.10.095_bib22","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.10.095_bib23","first-page":"1236","article-title":"Management of nodal indolent (non marginal-zone) non-Hodgkin\u2019s lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation","volume":"90","author":"Barosi","year":"2005","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.annonc.2023.10.095_bib24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2023.10.095_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.annonc.2023.10.095_bib26","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2023.10.095_bib27","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2023.10.095_bib28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"17","key":"10.1016\/j.annonc.2023.10.095_bib29","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/bloodadvances.2020002583","article-title":"Phase 1\/2a study of 177Lu-lilotomab satetraxetan in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"4","author":"Kolstad","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.annonc.2023.10.095_bib30","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2023.10.095_bib31","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.annonc.2023.10.095_bib32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.2020007994","article-title":"Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2023.10.095_bib33","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1200\/JCO.2022.40.16_suppl.7510","article-title":"Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial","volume":"40","author":"Zinzani","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.10.095_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11864-020-00746-8","article-title":"PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma","volume":"21","author":"Sapon-Cousineau","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.annonc.2023.10.095_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2021-145872","article-title":"Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) who have received \u22652 prior lines of therapy: pivotal results from a phase I\/II study","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.10.095_bib36","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2023.10.095_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2023.10.095_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423042400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423042400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:12:48Z","timestamp":1762319568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423042400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0923753423042400"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.10.095","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed\/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.10.095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}